ConductScience.org, home

Paper40940902

Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.

Kawczak P and 2 others. Cancers (Basel), 2025. Cited by 4 papers, by iCite.

Cite this record

ConductScience Library. Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma. Papers, record 40940902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
4
iCite
Revised in PubMed
2025-09-16
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kawczak PPiotrhttps://orcid.org/0000-0003-3902-2744
2Feszak IJIgor Jarosławhttps://orcid.org/0000-0003-0719-1754
3Bączek TTomasz

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References380

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128187290Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.Cell2017https://conductscience.org/library/papers/28187290PubMed
215734974Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review.Cancer Epidemiol Biomarkers Prev2005https://conductscience.org/library/papers/15734974PubMed
334986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
417255361Inhibitory effect of tumor cell-derived lactic acid on human T cells.Blood2007https://conductscience.org/library/papers/17255361PubMed
537536941Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck.J Immunother Cancer2023https://conductscience.org/library/papers/37536941PubMed
637146473Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.Lung Cancer2023https://conductscience.org/library/papers/37146473PubMed
734538402RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.Contemp Clin Trials2021https://conductscience.org/library/papers/34538402PubMed
835790315Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.J Immunother Cancer2022https://conductscience.org/library/papers/35790315PubMed
937511453Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer.Int J Mol Sci2023https://conductscience.org/library/papers/37511453PubMed
1040243372Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications.Immun Inflamm Dis2025https://conductscience.org/library/papers/40243372PubMed
1138398094Mechanisms of Resistance and Therapeutic Perspectives in Immunotherapy for Advanced Head and Neck Cancers.Cancers (Basel)2024https://conductscience.org/library/papers/38398094PubMed
1230576970
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
Eur J Cancer2019https://conductscience.org/library/papers/30576970PubMed
1335258987
Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O6-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.
J Clin Oncol2022https://conductscience.org/library/papers/35258987PubMed
1428885881Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.N Engl J Med2017https://conductscience.org/library/papers/28885881PubMed
1536877893First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?J Clin Oncol2023https://conductscience.org/library/papers/36877893PubMed
1634446053Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).Radiat Oncol2021https://conductscience.org/library/papers/34446053PubMed
1727718784Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.N Engl J Med2016https://conductscience.org/library/papers/27718784PubMed
1826406148Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.N Engl J Med2015https://conductscience.org/library/papers/26406148PubMed
1939725966Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.Mol Cancer2024https://conductscience.org/library/papers/39725966PubMed
2033303578Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease.J Immunother Cancer2020https://conductscience.org/library/papers/33303578PubMed

See all 380 referencesDownload CSV of references

Cited by4

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.

PMIDTitleJournalYearIn PapersSource
42401619Programmed cell death ligand 1(PD-L1) association in metastatic and non-metastatic oral squamous cell carcinoma: clinicopathologic and immunohistochemical study.Sci Rep2026https://conductscience.org/library/papers/42401619PubMed
42121986Immunohistochemical Study of the Tumor Immune Microenvironment in p16-Positive and p16-Negative Oral Squamous Cell Carcinoma and Its Prognostic Implications.Diagnostics (Basel)2026https://conductscience.org/library/papers/42121986PubMed
41683575Fibronectin Is a Likely Therapeutic Target Shared by Oral and Breast Carcinomas.Int J Mol Sci2026https://conductscience.org/library/papers/41683575PubMed
41097741Co-Stimulatory and Immune Checkpoint Molecule Expression on Peripheral Immune Cells Differs Age Dependently Between Healthy Donors and Patients with Head and Neck Squamous Cell Carcinoma.Cancers (Basel)2025https://conductscience.org/library/papers/41097741PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40940902

GET https://conductscience.org/api/papers/v1/40940902/references?page=2